Background Melanoma brain metastases (MBMs) are a challenging clinical problem with
high morbidity and mortality. Although first-line dabrafenib–trametinib and ipilimumab …

Opinion statement With greater understanding of underlying biology and development of
effective BRAF-targeted therapy and immunotherapy, along with remarkable advances in …

BACKGROUND The development of brain metastases is common for systemic treatment
failure in patients with melanoma and has been associated with a poor prognosis. Recent …

Background Preliminary data from the ABC (76 pts, med f/u 17mo) and CheckMate 204 (94
pts, med f/u 14mo) trials showed that nivo and nivo+ ipi have activity in active melanoma …

9009 Background: Brain metastases (BrMs) develop in 40% of metastatic melanoma (MM)
patients (pts). Untreated BrMs exclude from most clinical trials. In prior trials, treatment of MM …

Background Nivolumab combined with ipilimumab have shown activity in melanoma brain
metastasis (MBM). However, in most of the clinical trials investigating immunotherapy in this …

Purpose: Phase II trials have shown encouraging activity with ipilimumab plus fotemustine
and ipilimumab plus nivolumab in melanoma brain metastases. We report the primary …

Background In patients with melanoma and asymptomatic brain metastases (MBM),
nivolumab plus ipilimumab provided an intracranial response rate of 55%. Here, we present …

TPS9600 Background: Nivolumab combined with ipilimumab is active in melanoma brain
metastases, with intracranial response rates> 55% and durable survival in treatment naïve …

Background Brain metastases are a common cause of disabling neurologic complications
and death in patients with metastatic melanoma. Previous studies of nivolumab combined …